Vera Therapeutics (VERA) said Wednesday that it would expand the development of its lead asset, atacicept, following positive results from the ongoing phase 2 and 3 trials in patients with IgA nephropathy and other autoimmune kidney indications.
The company said it plans to initiate a study in Q4 to give its ongoing phase 2 and 3 trials participants extended access to atacicept before it becomes commercially available, allowing for the collection of longer-term data.
It added that in 2025, the company plans to launch a study to assess atacicept's efficacy and safety in expanded IgAN populations, including adults with varying levels of kidney function and adolescents at high risk of progression.
The study will also extend to autoimmune glomerular diseases like primary membranous nephropathy and focal segmental glomerulosclerosis.
Price: 44.20, Change: +1.37, Percent Change: +3.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。